MTEMQ — Molecular Templates Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$9.66m
- $57.31m
Brief: Molecular Templates Announces Executive Leadership Changes
Brief: Molecular Templates Announces Debt Payoff And Restructuring
U.S. STOCKS ON THE MOVE-Lands' End, Energy sector
U.S. STOCKS ON THE MOVE-Biogen, NetApp, LyondellBasell
U.S. STOCKS ON THE MOVE-Monopar Therapeutics, Molecular Templates, NRG Energy
Molecular Templates up as FDA removes partial clinical hold on cancer drug trial
Brief: Molecular Templates Announces The FDA Removal Of Partial Clinical Hold In The Phase 1 Clinical Trial For MT-0169 And Focuses On Extramedullary Myeloma
Molecular Templates Inc reports results for the quarter ended in March - Earnings Summary
Brief: Molecular Templates, Inc. Reports First Quarter 2023 Financial Results And Business Update
Molecular Templates Inc expected to post a loss of 28 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-International Game Technology, AMC Entertainment
U.S. STOCKS ON THE MOVE-Vuzix, Greenbrier, New Fortress Energy
Molecular Templates down after FDA's partial clinical hold on cancer therapy trial
Brief: Molecular Templates Announces Partial Clinical Hold For Phase 1 Study Of MT-0169
Brief: Molecular Templates Inc Says On April 4 Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. RESEARCH ROUNDUP-Apple, Intel, Tesla
Brief: Molecular Templates Inc Says Restructuring To Reduce Workforce By About 50%, Result In Cessation Of MT-5111 (HER2) Clinical Development Program
Molecular Templates Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Molecular Templates Announces IND Acceptance By FDA For MT-8421 ETB Program